デフォルト表紙
市場調査レポート
商品コード
1218681

バイオディフェンスの世界市場 2023

Biodefense

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 363 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
バイオディフェンスの世界市場 2023
出版日: 2023年01月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 363 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のバイオディフェンス市場は2030年に190億米ドルに達する

変化したCOVID-19後のビジネス環境において、2022年に134億米ドルと推定されるバイオディフェンスの世界市場は、2030年までに190億米ドルの修正規模に達し、分析期間2022-2030年に4.5%のCAGRで成長すると予測されます。本レポートで分析したセグメントの1つである炭疽菌は、CAGR3.5%を記録し、分析期間終了時には58億米ドルに達すると予測されます。パンデミック後の回復を考慮し、天然痘分野の成長率は今後8年間のCAGRを4.5%に修正しました。

米国市場は39億米ドル、中国はCAGR4.2%で成長予測

米国のバイオディフェンス市場は、2022年に39億米ドルと推定されます。世界第2位の経済大国である中国は、2022年から2030年にかけてのCAGRが4.2%で、2030年には34億米ドルの市場規模に達すると予測されています。その他の注目すべき地域市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ3.9%と3.8%の成長が予測されています。欧州では、ドイツがCAGR3.5%で成長すると予測されています。

調査対象企業の例

  • Achaogen, Inc.
  • Alexeter Technologies, LLC
  • Alnylam Pharmaceuticals, Inc.
  • Altimmune, Inc.
  • ANP Technologies, Inc.
  • Bavarian Nordic A/S
  • Cleveland BioLabs, Inc.
  • Elusys Therapeutics, Inc.
  • Emergent BioSolutions, Inc.
  • Ichor Medical Systems, Inc.
  • New Horizons Diagnostic Corporation
  • PathSensors, Inc.
  • Research International, Inc.
  • SIGA Technologies

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP-1831

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Biodefense Market to Reach $19 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Biodefense estimated at US$13.4 Billion in the year 2022, is projected to reach a revised size of US$19 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2022-2030. Anthrax, one of the segments analyzed in the report, is projected to record a 3.5% CAGR and reach US$5.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Smallpox segment is readjusted to a revised 4.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $3.9 Billion, While China is Forecast to Grow at 4.2% CAGR

The Biodefense market in the U.S. is estimated at US$3.9 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.4 Billion by the year 2030 trailing a CAGR of 4.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.9% and 3.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Select Competitors (Total 22 Featured):

  • Achaogen, Inc.
  • Alexeter Technologies, LLC
  • Alnylam Pharmaceuticals, Inc.
  • Altimmune, Inc.
  • ANP Technologies, Inc.
  • Bavarian Nordic A/S
  • Cleveland BioLabs, Inc.
  • Elusys Therapeutics, Inc.
  • Emergent BioSolutions, Inc.
  • Ichor Medical Systems, Inc.
  • New Horizons Diagnostic Corporation
  • PathSensors, Inc.
  • Research International, Inc.
  • SIGA Technologies

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Biodefense - Global Key Competitors Percentage Market Share in 2020 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2020 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Biodefense by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Biodefense by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 3: World 18-Year Perspective for Biodefense by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Anthrax by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Anthrax by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 6: World 18-Year Perspective for Anthrax by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Smallpox by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Smallpox by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 9: World 18-Year Perspective for Smallpox by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Botulism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Botulism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 12: World 18-Year Perspective for Botulism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Radiation / Nuclear by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Radiation / Nuclear by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 15: World 18-Year Perspective for Radiation / Nuclear by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 18: World 18-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
    • TABLE 19: World Biodefense Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biodefense Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 22: USA 18-Year Perspective for Biodefense by Product - Percentage Breakdown of Value Sales for Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products for the Years 2012, 2023 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 25: Canada 18-Year Perspective for Biodefense by Product - Percentage Breakdown of Value Sales for Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products for the Years 2012, 2023 & 2030
  • JAPAN
    • Biodefense Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 28: Japan 18-Year Perspective for Biodefense by Product - Percentage Breakdown of Value Sales for Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products for the Years 2012, 2023 & 2030
  • CHINA
    • Biodefense Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 31: China 18-Year Perspective for Biodefense by Product - Percentage Breakdown of Value Sales for Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products for the Years 2012, 2023 & 2030
  • EUROPE
    • Biodefense Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Biodefense by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Biodefense by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 34: Europe 18-Year Perspective for Biodefense by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2023 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 37: Europe 18-Year Perspective for Biodefense by Product - Percentage Breakdown of Value Sales for Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products for the Years 2012, 2023 & 2030
  • FRANCE
    • Biodefense Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 40: France 18-Year Perspective for Biodefense by Product - Percentage Breakdown of Value Sales for Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products for the Years 2012, 2023 & 2030
  • GERMANY
    • Biodefense Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 43: Germany 18-Year Perspective for Biodefense by Product - Percentage Breakdown of Value Sales for Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products for the Years 2012, 2023 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 46: Italy 18-Year Perspective for Biodefense by Product - Percentage Breakdown of Value Sales for Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products for the Years 2012, 2023 & 2030
  • UNITED KINGDOM
    • Biodefense Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 49: UK 18-Year Perspective for Biodefense by Product - Percentage Breakdown of Value Sales for Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products for the Years 2012, 2023 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 52: Rest of Europe 18-Year Perspective for Biodefense by Product - Percentage Breakdown of Value Sales for Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products for the Years 2012, 2023 & 2030
  • ASIA-PACIFIC
    • Biodefense Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 55: Asia-Pacific 18-Year Perspective for Biodefense by Product - Percentage Breakdown of Value Sales for Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products for the Years 2012, 2023 & 2030
  • REST OF WORLD
    • TABLE 56: Rest of World Recent Past, Current & Future Analysis for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Rest of World Historic Review for Biodefense by Product - Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 58: Rest of World 18-Year Perspective for Biodefense by Product - Percentage Breakdown of Value Sales for Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products for the Years 2012, 2023 & 2030

IV. COMPETITION